Scholarlink

Background <p>Lung adenocarcinoma brain metastasis (LUAD-BM) is a leading cause of cancer-related mortality, yet the genomic determinants driving brain tropism and reliable predictive biomarkers remain poorly defined.</p> Methods <p>We analyzed the mutational profiling of 2602 primary LUAD and LUAD-BM samples. Differentially mutated genes were used to construct a mutational signature–based classification for BM tropism, which was further characterized by corresponding multi-omic data. Independent validation was conducted in TCGA (<i>N</i> = 503) and Oncosg (<i>N</i> = 302) cohorts.</p> Results <p>Mutational profiling of 172 LUAD-BM revealed frequent alterations in TP53, EGFR, and KRAS, with enrichment of apoptosis-, E2F-, and cell cycle–related pathways. Twenty-five genes were identified as significantly more frequently mutated in LUAD-BM, most of which also displayed higher mutation allele frequencies and preferential enrichment in LUAD patients with isolated brain metastasis. Using this 25-gene mutational signature, primary LUAD samples were classified into three distinct clusters with significantly different survival outcomes. Cluster 3 was strongly associated with brain metastasis, accounting for 62% of LUAD-BM cases and 59% of LUAD patients with isolated brain metastasis, and showed the highest incidence of BM development (25.3%, <i>P</i> &lt; 0.001). Meanwhile, Cluster 3 was characterized by markedly elevated TMB, extensive copy number variations across multiple chromosomes, and an almost universal TP53 mutation rate (99.9%), representing a highly unstable genomic subtype resembling LUAD-BM. The prognostic value of this classification was independently validated in TCGA-LUAD and Oncosg cohorts, where the mutation-defined clusters retained distinct survival patterns and genomic features. Transcriptomic analyses further demonstrated that Cluster 3 was enriched for cell cycle, mitotic, and chemokine signaling pathways, whereas Cluster 1 showed activation of lung function–associated pathways, highlighting the biological and clinical relevance of the mutation-based stratification.</p> Conclusion <p>We identified a high-risk LUAD subtype defined by a distinct mutational and copy number landscape, providing a practical framework for brain metastasis risk stratification and potential guidance for targeted surveillance strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A mutational signature for brain metastasis tropism in lung adenocarcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月6日

查看全文
  • Chuanbao Zhang,
  • Runping Hou,
  • Yangyang Wang,
  • Shucheng Jin,
  • Hanjie Liu,
  • Shunchang Ma,
  • Zhan Xue,
  • Lei Xing,
  • Wang Jia

摘要

Background

Lung adenocarcinoma brain metastasis (LUAD-BM) is a leading cause of cancer-related mortality, yet the genomic determinants driving brain tropism and reliable predictive biomarkers remain poorly defined.

Methods

We analyzed the mutational profiling of 2602 primary LUAD and LUAD-BM samples. Differentially mutated genes were used to construct a mutational signature–based classification for BM tropism, which was further characterized by corresponding multi-omic data. Independent validation was conducted in TCGA (N = 503) and Oncosg (N = 302) cohorts.

Results

Mutational profiling of 172 LUAD-BM revealed frequent alterations in TP53, EGFR, and KRAS, with enrichment of apoptosis-, E2F-, and cell cycle–related pathways. Twenty-five genes were identified as significantly more frequently mutated in LUAD-BM, most of which also displayed higher mutation allele frequencies and preferential enrichment in LUAD patients with isolated brain metastasis. Using this 25-gene mutational signature, primary LUAD samples were classified into three distinct clusters with significantly different survival outcomes. Cluster 3 was strongly associated with brain metastasis, accounting for 62% of LUAD-BM cases and 59% of LUAD patients with isolated brain metastasis, and showed the highest incidence of BM development (25.3%, P < 0.001). Meanwhile, Cluster 3 was characterized by markedly elevated TMB, extensive copy number variations across multiple chromosomes, and an almost universal TP53 mutation rate (99.9%), representing a highly unstable genomic subtype resembling LUAD-BM. The prognostic value of this classification was independently validated in TCGA-LUAD and Oncosg cohorts, where the mutation-defined clusters retained distinct survival patterns and genomic features. Transcriptomic analyses further demonstrated that Cluster 3 was enriched for cell cycle, mitotic, and chemokine signaling pathways, whereas Cluster 1 showed activation of lung function–associated pathways, highlighting the biological and clinical relevance of the mutation-based stratification.

Conclusion

We identified a high-risk LUAD subtype defined by a distinct mutational and copy number landscape, providing a practical framework for brain metastasis risk stratification and potential guidance for targeted surveillance strategies.